- Home
- MAPS vs ACRS Comparison
MAPS vs ACRS Comparison
Compare MAPS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAPS
- ACRS
- Stock Information
- Founded
- MAPS 2008
- ACRS 2012
- Country
- MAPS United States
- ACRS United States
- Employees
- MAPS N/A
- ACRS N/A
- Industry
- MAPS Computer Software: Prepackaged Software
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- MAPS Technology
- ACRS Health Care
- Exchange
- MAPS Nasdaq
- ACRS Nasdaq
- Market Cap
- MAPS 131.9M
- ACRS 127.6M
- IPO Year
- MAPS N/A
- ACRS 2015
- Fundamental
- Price
- MAPS $1.12
- ACRS $1.26
- Analyst Decision
- MAPS Strong Buy
- ACRS Strong Buy
- Analyst Count
- MAPS 1
- ACRS 7
- Target Price
- MAPS $2.61
- ACRS $10.67
- AVG Volume (30 Days)
- MAPS 613.4K
- ACRS 801.8K
- Earning Date
- MAPS 05-08-2025
- ACRS 05-08-2025
- Dividend Yield
- MAPS N/A
- ACRS N/A
- EPS Growth
- MAPS N/A
- ACRS N/A
- EPS
- MAPS 0.08
- ACRS N/A
- Revenue
- MAPS $184,737,000.00
- ACRS $17,777,000.00
- Revenue This Year
- MAPS $0.86
- ACRS N/A
- Revenue Next Year
- MAPS $12.85
- ACRS $425.96
- P/E Ratio
- MAPS $13.66
- ACRS N/A
- Revenue Growth
- MAPS N/A
- ACRS N/A
- 52 Week Low
- MAPS $0.70
- ACRS $0.95
- 52 Week High
- MAPS $1.65
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- MAPS 45.59
- ACRS 43.64
- Support Level
- MAPS $1.11
- ACRS $1.20
- Resistance Level
- MAPS $1.21
- ACRS $1.46
- Average True Range (ATR)
- MAPS 0.07
- ACRS 0.11
- MACD
- MAPS 0.00
- ACRS 0.02
- Stochastic Oscillator
- MAPS 32.14
- ACRS 41.77
About MAPS WM Technology Inc.
WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on our marketplace ads.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.